Analyzing differences in gut microbiota in secondary failure of sulfonylureas through 16S rDNA sequencing and metabolomics
Food and Chemical Toxicology · 2026-09 · 215 · 116180
DOI: 10.1016/j.fct.2026.116180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2026-09. Verfasst von Qingxian Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hainan West Central Hospital, Danzhou, Hainan, China. Hauptthemen laut MEDLINE: Sulfonylurea Compounds, Metabolomics, RNA, Ribosomal, 16S, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, sulfonylureas, a class of medications used in type 2 diabetes mellitus (T2DM) treatment, are widely applied, but the problem of secondary failure isn't fully understood. This study aims to explore the potential mechanisms of secondary failure of sulfonylureas (SFS) and to identify reliable predictive biomarkers. In this study, 16S rDNA sequencing technology and non-targeted metabolomics were used to analyze the differences in gut microbiota and metabolic products between the SFS and sulfonylurea effective (SE) groups. The results of 16S rDNA sequencing indicated that there are differences in composition between two groups. Seventeen different bacterial types were identified, including six types from SFS patients and eleven from SE. SFS might be linked to disturbances in energy metabolism, amino acid metabolism, nucleotide metabolism, and lipid metabolism within the gut microbiota. Metabolomics results showed 66 different metabolites between two groups (49 metabolites were upregulated, and 17 metabolites were downregulated). Correlation analysis between gut bacteria and fecal metabolites revealed that 4 types of gut bacteria were significantly linked to 5 types of metabolites. This study reveals distinct gut microbiota composition in patients with sulfonylurea secondary failure, helping us understand changes in gut metabolites and providing new biomarkers for personalized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hainan West Central Hospital, Danzhou, Hainan, China.
- Department of Endocrinology, Hainan West Central Hospital, Danzhou, Hainan, China.
- Department of Laboratory Medicine, Hainan West Central Hospital, Danzhou, Hainan, China.
- Department of Pharmacy, Hainan West Central Hospital, Danzhou, Hainan, China. Electronic address: chenqq021@163.com.
Zitieren
APA
Chen, Q., Liu, L., Zhang, C., Su, P., Li, D., Zheng, Y., & Chen, Q. (2026). Analyzing differences in gut microbiota in secondary failure of sulfonylureas through 16S rDNA sequencing and metabolomics. Food and Chemical Toxicology, 215, 116180. https://doi.org/10.1016/j.fct.2026.116180
Vancouver
Chen Q, Liu L, Zhang C, Su P, Li D, Zheng Y, et al. Analyzing differences in gut microbiota in secondary failure of sulfonylureas through 16S rDNA sequencing and metabolomics. Food and Chemical Toxicology. 2026;215:116180. doi:10.1016/j.fct.2026.116180
BibTeX
@article{Chen2026,
author = {Chen, Qingxian and Liu, Lixia and Zhang, Cuilan and Su, Peiqiong and Li, Dingfu and Zheng, Yu and Chen, Qingqing},
title = {Analyzing differences in gut microbiota in secondary failure of sulfonylureas through 16S rDNA sequencing and metabolomics},
journal = {Food and Chemical Toxicology},
year = {2026},
volume = {215},
pages = {116180},
doi = {10.1016/j.fct.2026.116180}
}
EUVIMED